https://www.targetedonc.com/view/fda-grants-fast-track-designation-to-novel-tkk1-therapy-for-er-her2--advanced-breast-cancer
The investigational drug, CFI-402257, has earned the FDA’s attention for promising preclinical results, and is now under investigation in a phase 1 study.
Create an account or login to join the discussion